Marksans Pharma Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results, which include consolidated and standalone figures. Key developments during the quarter include the acquisition of 100% share capital of QliniQ B.V. for EUR 7.50 Million and the grant of 300,000 stock options to employees.
Marksans Pharma Board Approves Q1 FY27 Results
Marksans Pharma Limited’s Board of Directors convened on August 12, 2026, to review and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The company confirmed that the Limited Review Reports from its statutory auditors, M/s. MSKA & Associates LLP, were unmodified.
Key Financial Highlights (Standalone)
For the quarter ended June 30, 2026, Marksans Pharma reported total income of ₹3,386.57 million. Total expenses amounted to ₹2,481.99 million, leading to a Profit Before Tax (PBT) of ₹904.58 million. After accounting for a total tax expense of ₹214.21 million, the Profit After Tax (PAT) stood at ₹690.37 million. Total Comprehensive Income for the period was ₹692.97 million.
Strategic Acquisitions and Developments
During the quarter, Marksans Pharma completed the acquisition of 100% of the share capital of QliniQ B.V., a Netherlands-based company specializing in innovative healthcare solutions, for a consideration of EUR 7.50 Million. QliniQ B.V. is a subsidiary effective from April 1, 2026. Additionally, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees.
Subsequent to the quarter, Marksans Pharma entered into an agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company, for EUR 1.10 Million. This acquisition was also completed, making ABCnow GmbH a wholly owned subsidiary.
Financial Performance (Consolidated)
On a consolidated basis for the quarter ended June 30, 2026, total income reached ₹8,662.00 million, with total expenses of ₹6,596.29 million. The consolidated Profit Before Tax was ₹2,065.71 million, and after a tax expense of ₹471.64 million, the consolidated Profit After Tax stood at ₹1,594.07 million. Total Comprehensive Income on a consolidated basis was ₹1,764.31 million.
Website Availability
The standalone and consolidated unaudited financial results are available on the company’s website at www.marksanspharma.com and on the websites of the BSE and NSE.
Source: BSE
